PERSON
Minerva’s Roluperidone for Schizophrenia Symptoms Denied Approval by FDA
United States Food and Drug Administration, MFSD1 gene, Symptoms aspect, Schizophrenia, New Drug Application
Minerva Entangles in Web of FDA Rejection Again Over Schizophrenia Drug Roluperidone
United States Food and Drug Administration, MFSD1 gene, Schizophrenia
Venatorx Confident in Quick Resolution of Manufacturing Concerns for Cefepime-Taniborbactum Antibiotic Despite FDA Setback
United States Food and Drug Administration, Venatorx, CID, 2024-02-23, cefepime-taniborbactam, Manufacture
Improving Amylyx’s ALS Drug Relyvrio: Taste Masking and Withdrawal
Amylyx, ALS, Relyvrio, Taste Masking, Withdrawal, Patent Life
Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
AbbVie CEO Gonzalez to Step Down, Robert Michael named Successor in Seamless Transition
Gonzalez, AbbVie’s, company’s, Transition Mutation
Bayer Implements 95% Dividend Cut to Reduce Debt Amid CEO Bill Anderson’s Turnaround Plan
Bayer, Euro currency, Reduced, 95%
FDA Approves Xolair (Omalizumab) for Reducing Severe Outcomes from Multiple Food Allergies
Xolair, United States Food and Drug Administration, omalizumab, Hypersensitivity, Food, Reduced, Severe (severity modifier)
Revolutionary Protein Degraders Integrated into Antibody-Drug Conjugates: Carolyn Bertozzi and Versant Launch New Biotech with $94 Million Funding
Carolyn Bertozzi, Versant Ventures, Firefly Bio, Protein degraders, Antibody-drug conjugates (ADCs), Degrader-Antibody Conjugates (DACs), $94 million funding
Eicos Sciences’ Aurlumyn: First FDA-Approved Treatment for Severe Frostbite Reduces Amputation Risk
Aurlumyn, Eicos, Amputation, Sciences’, iloprost, severe frostbite